Ronald Levy M.D. ’68, Stanford School of Medicine professor and associate director of the Stanford Cancer Institute (SCI), unveiled the research that led to the breakthrough cancer medication Rituxan.
A tumor antigen must be sufficiently immunogenic to induce antibody production, and immunogenicity is determined by the strength of presentation by major histocompatibility complex (MHC)-encoded ...
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay ...
Researchers at Fred Hutchinson Cancer Center have developed a new hybridoma cell line that expresses mouse anti-human NKG2D antibodies. Reference: Bauer, et al., Science. 1999; 285(5428):727-9.
Researchers at Fred Hutchinson Cancer Center have developed a new hybridoma cell line that expresses anti-miniSOG antibodies. MiniSOG is a fluorescent flavoprotein engineered from Arabidopsis ...
The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...
Antibody engineering and production are essential tools in drug discovery, providing powerful and specific therapeutics and diagnostic/prognostic materials for various diseases. Antibodies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results